[iito] Business Intelligence’s Post

#KeiretsuBacked Virion Therapeutics, LLC reports promising Phase 1b clinical results for VRON-0200, a first-in-class checkpoint modifier for HBV functional cure, at The Liver Meeting® 2024. The study highlights significant T-cell responses and a notable decline in HBV surface antigen among chronically infected patients, showcasing a pivotal step toward advancing immunotherapy for hepatitis B. Learn more: https://lnkd.in/dQFjBktQ

🏆Congratulations to our partners at Ascentawits Pharma for receiving the "Outstanding Paper Award" at CSCO! OBI Pharma's partner, Ascentawits Pharma Ltd., presented promising interim results for AST-3424 (OBI-3424) at #CSCO2024: Phase II study in advanced hepatocellular carcinoma (HCC) Median OS: 10.8 months (12.3 months for 2nd line+) ORR: 6.7%, DCR: 60.0% Potential new option for late-line HCC patients Key highlights: ✅ Encouraging survival benefits ✅ Good safety profile ✅ Effective in patients who progressed after immunotherapy AST-3424, a first-in-class AKR1C3-activated prodrug developed by OBI Pharma, shows promise for HCC patients with limited options. OBI Pharma continues to collaborate closely with Ascentawits through the sharing of clinical data and information. #OBI3424 #CancerResearch #ClinicalTrials #LiverCancer #Partnership https://lnkd.in/gEd4bubg

NX-1607: FIRST-IN-CLASS SMALL MOLECULE INHIBITOR OF CBL-B IN THE IMMUNO-ONCOLOGY FIELD Recurrent diffuse large B cell lymphoma (DLBCL) remains a high unmet medical need despite advances in treatment such as cell- and immune-mediated therapies. Based on United States (U.S.) cancer registry data, age-standardized incidence rate for DLBCL was 7.2 per 100,000. DLBCL incidence rises with age and is generally higher in males than females; in the U.S., incidence is highest among non-Hispanic whites (9.2/100,000). The emergence of resistance to current therapies, including to T cell-mediated therapies such as CAR-T and T cell engagers underscores the need for novel therapies that can enhance T cell function, counteract a suppressive tumor microenvironment (TME) and prevent tumor escape associated with low tumor antigen expression. Casitas B-lineage lymphoma proto-oncogene B (CBL-B) is an E3 ubiquitin ligase expressed in immune cells and is a master regulator of T, NK, and dendritic cell activation, collectively curtailing their anti-tumor functionality. NX-1607 is an oral, first-in-class small molecule inhibitor of Casitas B-lineage Lymphoma B (CBL-B) for immuno-oncology, that has been shown to enhance antigen recall, reduce T cell exhaustion and increase cytokine production upon T cell receptor stimulation, overcoming suppressive signals from the TME. Moreover, preclinical studies in mouse lymphoma models have demonstrated that NX-1607 can induce robust, T cell-dependent tumor regression. By bolstering the effectiveness of inherent T- and NK-mediated anti-tumor responses and enhancing antigen recall, NX-1607 offers potential as a supportive and rejuvenating agent for CAR-T or NK cell therapies in patients with hematologic malignancies who have developed resistance. Here, a real med chem tour-de-force from Frederick Cohen and the talented Nurix Therapeutics team. #NX_1607 #immuno_oncology #DLBCL. Reported by https://lnkd.in/dckZk78C

📢Breakthrough Pediatric Cancer Drug Acquired by Essential Pharma 📢 Essential Pharma has acquired Renaissance Pharma Ltd in order to commercialize the company's Phase II program Hu14.18K322A in pediatric high-risk neuroblastoma. The acquisition price was not disclosed. The Phase II study showed promising results with an event-free 3-year survival rate of 73.7% and an overall survival rate of 86% in previously untreated children with high-risk neuroblastoma. This acquisition adds a second product candidate to Essential Pharma's rare disease portfolio. #BioprocessUpdates #EssentialPharma #RenaissancePharma #acquisition #pharmaceuticals #pediatricneuroblastoma #raredisease #PhaseIIstudy #Hu14.18K322A #survivalrates #promisingresults ▷ Read the full article here: 📎 https://lnkd.in/eAS4CGSz

We are pleased to share our latest article exploring the oral delivery of #oligonucleotide therapeutics targeted against gastrointestinal (GI) diseases and cancers authored by N4 Pharma CEO Nigel Theobald. A promising route to success in this field is via our engineered silica nanoparticle, Nuvec®, which has a unique irregular surface structure that effectively traps and protects #siRNA as it migrates to the target cells, making it well suited to successful oral administration. Read the article published in the latest issue - and featured on the cover - of ONdrugDelivery here: https://lnkd.in/eZCAA-5N

Ibrance significantly boosts survival rates in breast cancer patients 🎗️ Pfizer Know complete story - https://lnkd.in/dfv_ZRQx FDA commences review of Ascendis Pharma’s TransCon hGH for growth hormone deficiency 🩺 Know complete story - https://lnkd.in/dB2UDdJS ARS Pharmaceuticals, Inc. seeks global approval for NEFFY®, a needle-free epinephrine spray 🌍 Know complete story - https://lnkd.in/dsJJxSYH Takeda’s late-stage pipeline highlights breakthroughs in novel therapies 🔬 Know complete story - https://lnkd.in/di5q2fkj #Ibrance #BreastCancer #AscendisPharma #TransConhGH #ARSPharma #NEFFY #Takeda #BreakthroughTherapies

[ALA Client News] BiPER Therapeutics raises €800,000 in bridge funding to advance its first-in-class BiP-inhibitor for gastrointestinal cancers to clinical trials   ✅ Non-dilutive bridge funding marks important milestone ahead of planned closure of Series A funding in 2025, providing means to progress BPR001-615 regulatory preclinical development and prepare for initial clinical trials    ✅ Start-up will be attending 2025 J.P. Morgan Healthcare Conference in San Francisco (US) from January 13–16, to showcase progress and meet investors   👉 https://lnkd.in/eWNFhXFm   Mehdi Chelbi Mathilde Iclanzan WiSEED Quest for health  #JPMorgan #gastriccancer

On October 10, 2024, the Food and Drug Administration approved inavolisib (Itovebi, Genentech, Inc.) with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic #breastcancer, as detected by an #FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. FDA also approved the FoundationOne Liquid CDx assay as a companion diagnostic device to identify patients with breast cancer for treatment with inavolisib with palbociclib and fulvestrant. FDA #precisionmedicine #cancercare

We’re thrilled to announce an investment by Novo Nordisk which will support development of our lead candidate EKZ-102 for ALS and other neurodegenerative diseases and enable the advancement of our novel HDAC6 inhibitors as potential disease-modifying therapeutics for cardiorenal disease. EKZ-102 is a highly selective, uniquely CNS-penetrant HDAC6 inhibitor with strong potential to be a first-in-class, disease-modifying therapy for ALS and other indications. Read the PR here: https://lnkd.in/eYSJcTBp